Reviewed by Michael Gill, B. Sc.
9 Plasma Cell Leukemia Clinical Trials Near Me
Top Hospitals for Plasma Cell Leukemia Clinical Trials
Image of Masonic Cancer Center at University of Minnesota in Minnesota.
Masonic Cancer Center at University of Minnesota
Minneapolis
2Active Trials
3All Time Trials for Plasma Cell Leukemia
2017First Plasma Cell Leukemia Trial
Image of Mayo Clinic in Minnesota.
Mayo Clinic
Rochester
2Active Trials
3All Time Trials for Plasma Cell Leukemia
2011First Plasma Cell Leukemia Trial
Top Cities for Plasma Cell Leukemia Clinical Trials
Image of Minneapolis in Minnesota.
Minneapolis
3Active Trials
Masonic Cancer Center at University of MinnesotaTop Active Site
Image of Seattle in Washington.
Seattle
2Active Trials
Fred Hutch/University of Washington Cancer ConsortiumTop Active Site
Plasma Cell Leukemia Clinical Trials by Phase of Trial
Phase 1 Plasma Cell Leukemia Clinical Trials
1Active Plasma Cell Leukemia Clinical Trials
1Number of Unique Treatments
0Number of Active Locations
Plasma Cell Leukemia Clinical Trials by Age Group
Most Recent Plasma Cell Leukemia Clinical Trials
Top Treatments for Plasma Cell Leukemia Clinical Trials
Treatment Name
Active Plasma Cell Leukemia Clinical Trials
All Time Trials for Plasma Cell Leukemia
First Recorded Plasma Cell Leukemia Trial
High Throughput Screening
1
1
2018
HSCT with TBI Regimen
1
1
2018
TBI
1
2
2017
Ixazomib Citrate
1
2
2015
Panobinostat
1
1
2015

What Are Plasma Cell Leukemia Clinical Trials?

Plasma Cell Leukemia can be described as a rare yet aggressive type of cancer. It occurs in bone marrow plasma. However, the cancerous cells gradually travel out of the bone marrow penetrating the blood. The condition is a multiple myeloma subtype. Multiple myeloma occurs when the bone marrow plasma cells become uncontrollable. Hence, they weaken the bones, organs, and immune system. Furthermore, patients with plasma cell leukemia may also suffer from anemia.

Some plasma cell leukemia symptoms are bone pain, fatigue, irregular heartbeat, kidney damage, enlarged spleen, high blood calcium levels, and recurring infections.

Plasma cell leukemia clinical trials focus on developing a better understanding of the disease. These studies help assess, evaluate and determine the best treatments and therapies.

Why Is Plasma Cell Leukemia Being Studied Through Clinical Trials?

Plasma cell leukemia affects 1 out of every million people annually. As the condition is aggressive and spreads fast into the blood, the average survival rate of the patient is only a year after its diagnosis. Furthermore, it is more common in Black Americans than white people and slightly more common in males than females. Among the leading risk factors are genetic changes and exposure to environmental toxins.

Currently, available treatments can only slow the spread but not cure the disease. Therefore, Plasma cell leukemia clinical trials are being conducted to find the exact cause and cure. Moreover, these studies also help determine how the condition impact lives, how fast it can be diagnosed, and ways to prevent the risk.

What Are the Types of Treatments Available for Plasma Cell Leukemia?

Treatments available can help manage symptoms and prolong lives. These include chemotherapy and steroids. Chemotherapy is effective for killing cancer cells but can kill healthy cells too. On the other hand, steroids help change how the patient’s body responds to cancer. It can help alleviate symptoms and prevent complications. Besides this, experimental treatments are also being carried out by doctors for plasma leukemia cells.

What Are Some Recent Breakthrough Clinical Trials for Plasma Cell Leukemia?

2021: Plasma Cell Leukemia: A Review of 3 Cases Managed in Kenya- After the evaluation of three different cases of PCL (in terms of diversity and variability), it was concluded that novel agents, when followed by ASCT (autologous stem cell transplant) result in better outcomes.  

2022: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy- The report shows that CART therapy positively affects patients with PCL. It can effectively decrease the tumor load while improving patients' disease conditions and prolonging their survival.

Who Are Some of the Key Opinion Leaders/Researchers/Institutions Conducting Plasma Cell Leukemia Clinical Trial Research?

Francis K. Buadi MD

Dr. Buadi is a leading and recognized Hematologist. He is also an assistant professor at Mayo Clinic. He is well-reputed for his research work in Plasma cell disorders, stem cell transplantation, and bone marrow transplant.

Multiple Myeloma Research Foundation

The MMRF is dedicated to discovering new treatments and accelerating clinical trials in cancer research. It aims to find a cure for patients with multiple myeloma/PCL.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: November 8th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.